Skip to main content

Table 1 Summary of the main characteristics of the included studies

From: Prognostic and clinicopathologic significance of circZFR in multiple human cancers

Author

Year

Country

Cancer type

Clinical stage

Sample size

Cut-off value

Follow-up (months)

Detection method

Adjuvant therapy

Survival analysis

Outcome measure

NOS

Cedric, B [15]

2020

China

HCC

T1–T4

62

Mean

qRT–PCR

None

Univariate

CP

7

Chen, Z [19]

2020

China

BrC

I–IV

70

Median

60

qRT–PCR

N/A

Univariate

OS, CP

9

Fang, N [23]

2020

China

ESCC

I–IV

58

Median

qRT–PCR

None

Univariate

CP

7

Huang, S [21]

2020

China

GC

60

N/A

60

qRT–PCR

None

Univariate

OS

8

Huang, W [24]

2020

China

BlC

55

Median

60

qRT–PCR

None

Univariate

OS, DFS

8

Li, L [25]

2021

China

HCC

I–III

49

N/A

qRT–PCR

None

Univariate

CP

7

Lin, Y [26]

2021

China

HCC

I–IV

50

Median

60

qRT–PCR

None

Multivariate

OS,CP

9

Liu, M [20]

2020

China

BrC

I–IV

65

Median

54

qRT–PCR

None

Univariate

OS, CP

8

Liu, W [16]

2018

China

LC

44

N/A

80

qRT–PCR

None

Univariate

OS

8

Luo, L [27]

2021

China

BlC

I–IV

60

N/A

78

qRT–PCR

N/A

Univariate

OS,CP

8

Tan, A [28]

2019

China

HCC

80

Mean

60

qRT–PCR

None

Univariate

OS

8

Wei, H [17]

2018

China

PTC

41

N/A

60

qRT–PCR

N/A

Univariate

OS

8

Xu, R [29]

2021

China

HCC

I–IV

40

N/A

qRT–PCR

None

Univariate

CP

7

Yang, X [30]

2019

China

HCC

I–IV

30

Median

qRT–PCR

None

Univariate

CP

7

Zhang, P [22]

2017

China

CRC

I–IV

170

N/A

qRT–PCR

None

Univariate

CP

7

Zhang, W [18]

2019

China

BlC

Ta–T4

104

Median

72

qRT–PCR

None

Univariate

OS, PFS, CP

9

Zhan, W [31]

2020

China

HCC

I–IV

60

N/A

100

qRT–PCR

None

Univariate

OS, CP

9

  1. Abbreviations: BlC bladder cancer, BrC breast cancer, CRC colorectal cancer, CP clinicopathological parameters, DFS disease-free survival, ESCC esophageal squamous cell cancer, GC gastric cancer, HCC hepatocellular carcinoma, LC lung cancer, N/A not available, NOS Newcastle-Ottawa Scale, OS overall survival, PFS progression-free survival, PTC papillary thyroid cancer, qRT-PCR quantitative real-time polymerase chain reaction